In a market flooded with longevity startups promising to reverse aging, JangoBio enters with a specific, biological approach: restoring hormone balance through regenerative stem cell therapies. But with only 22 employees and sub-$5M revenue, the question isn't just about science—it's about survival in a capital-intensive industry.

"They're not chasing broad longevity claims—they're surgically targeting hormone restoration, a niche that could be both scientifically valid and commercially defensible."

The tech stack reveals a startup in early but serious mode. They're using jQuery and core-js—standard but slightly dated libraries—alongside Tailwind CSS and Bootstrap for rapid frontend development. Google Analytics tracks performance, while RSS feeds suggest they're maintaining some content strategy. The lack of advanced tracking or modern frameworks (like React or Vue) suggests they're prioritizing functionality over flashy user experiences. This is pragmatic for a biotech where the science matters more than the website aesthetics.

• Targeting hormone restoration via stem cells—a niche within the broader longevity market
• Revenue of $3.4M on 22 employees suggests ~$154K revenue per employee, typical for early-stage biotech
• Social presence on Twitter, Facebook, and LinkedIn, but no visible content strategy driving engagement
• No funding data publicly available—likely bootstrapped or in stealth mode for institutional capital
• Traffic sources are murky: 90.2% 'undefined' country suggests either technical issues or international testing